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for the friends and colleagues of the Department of Medicine at Jefferson Medical College

Center for Translational
Medicine Opens Its Doors
Chairman of the Department, noted,
“as there are only five such centers in
the country, this facility demonstrates
Jefferson’s commitment to the most
progressive efforts in medicine.”

Howard Weitz, MD, thanks Eugene Feiner
for his generosity in supporting one of the
Center for Translational Medicine’s new
laboratories, as Department Chairman
Arthur Feldman, MD, PhD (far left),
and Center Director Walter Koch, PhD
(far right), look on.

Center Director Walter Koch, PhD, also
thanked business leader Eugene Feiner,
whose generosity helped make possible
the Center’s Laboratory for Vascular
Biology and Thrombosis. “We are proud
to contribute research that will make a
difference in the lives of many patients
for years to come,” said Dr. Koch.
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Chairman
This issue of
Translations highlights
some landmark events
in the history of the
Department of
Medicine here at
Jefferson. First, Phase I
of our new Center for
Translational Medicine opened after nearly
a year of renovation. I hope you will enjoy a
profile of the Center’s Director, Walter Koch,
PhD. Future issues will feature interviews
with other new recruits for the Center. The
naming of the Eugene Feiner Laboratory for
Vascular Biology and Thrombosis is the first
of what we hope will be several investments
from friends and patients in the very best
we have to offer the future of medicine.
The Center for Translational Medicine is
the newest but not the only effort in the
Department to move discoveries at the
laboratory bench to the bedside. This issue
of Translations focuses on several other
new and exciting changes and advances
made in the field of technology transfer as
well as the divisions of Medical Oncology
and Infectious Diseases.

On November 14, 2003, the Department
of Medicine celebrated the opening
of the new Center for Translational
Medicine. Located on the 4th floor of
the College Building at 1025 Walnut,
the new Center boasts state-of-the-art
laboratory space as well as offices for its
growing staff.
In his remarks Arthur Feldman, MD, PhD,
Magee Professor of Medicine and

From the

Dr. Feldman and Dr. Koch join Andrea
Eckhart, PhD, who heads the Laboratory
for Vascular Biology and Thrombosis, and
benefactor Eugene Feiner in celebrating the
opening of the Center.

In attendance at the opening were many
of Mr. Feiner’s friends and family, as well
as a large number of Department of
Medicine Staff. Geno Merli, MD,
remarked that this was “a great day to
celebrate the future of the Department
of Medicine.”
For more information see the profile of
Eugene Feiner on p. 5 and the profile of
Dr. Koch on p. 2.

I was thrilled to take part in the hospital’s
125th Gala event honoring one of our very
best and brightest: Dr. Bernard Segal, who
continues to chart our course in cardiology
in these changing times. More than a mentor
to his colleagues, and more than a doctor
to those under his care, Bernie is an exceptional individual who raises the quality of
life of all he touches. We all look forward
to many more years of good work together.
In these exciting but also challenging times
I am proud to list the many ways in which
the Department of Medicine is making
critical contributions. I look forward to
sharing those advances with you in the
coming months.

Arthur M. Feldman, MD, PhD
Magee Professor of Medicine
and Chairman of the Department

Published by Jefferson Digital Commons, 2009
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Koch Directs the Growth of the Center
Some of the University’s most exciting
research efforts are being conducted
under the leadership of Walter J. Koch,
PhD. A distinguished researcher from
Duke University Medical Center, Dr. Koch
joined Jefferson in September 2003 as
Director of the Center for
Translational Medicine,
the Department of
Medicine’s progressive
initiative to use cuttingedge laboratory research
to create the best in
clinical care.

Walter J. Koch, PhD, the W. W.
Smith Professor of Medicine
and Director of the Center for
Translational Medicine

Dr. Koch feels the Center offers a unique
research and clinical opportunity to bring
laboratory discoveries “from the bench
to the bedside.” “There are other
cardiology research institutes,” he says,
“but the Center seeks to do more
all-encompassing research that will allow
physicians potentially to tailor drugs and
other therapies to individual patients,
and use genetic indicators to alter
disease outcomes.”
Of the center’s four main cores, gene
and cell therapy is Dr. Koch’s area of
expertise. This changes the function of
organs and/or cells by turning on certain
mechanisms. He has used genetically
engineered mouse models and viral
mediated genes and transferred them to
larger animal models (“I’m very successful at curing heart failure in mice,” he
notes modestly). In rabbits, for example,
Dr. Koch delivered genes through a single coronary artery. He noticed changes
within just eight hours and found he

could prolong the animals’ lives. The
goal here at Jefferson,” says Dr. Koch,
“is to take that paradigm of cellular
studies, small and large animal studies,
and expand them to other areas of
targets and diseases.”
An initial focus for Dr. Koch as Director
of the Center has been to recruit new
faculty for the Center’s four main cores.
“New recruits will build upon the strong
foundation laid by Dr. Paolo Fortina as
well as the research goals of the
Department of Medicine and the
institution,” says Dr. Koch.
“We seek to have the science in place
as a resource, so that any Jefferson
doctor can come to us, describe a
unique situation in a patient, and
engage our assistance, through basic
and translational research,” says Dr.
Koch. “This is a gradual process, but
we are confident that the impact will
be significant.”

Medical Oncology

Flomenberg Builds on Past Success
2003 was a year of recognition for Neal
Flomenberg, MD. He was awarded
Jefferson’s distinguished Simon Gratz
Research Prize and also named Director
of the Division of Medical Oncology, of
which he has been Acting Director since
2001. Professor of Microbiology and
Immunology and a bone marrow
transplant expert, he was named the
Leukemia and Lymphoma Society’s
2003 Man of the Year for Eastern
Pennsylvania. Since coming to Jefferson
in 1994 he has also been Director of
Medical Oncology’s Hematologic
Malignancies and Hematopoletic Stem
Cell Transplant Program.
“My success has largely been based
on the success of my colleagues, junior
faculty, and staff,” Dr. Flomenberg says.
But his strong leadership also reflects a
vision for translating the hard work of
his team into powerful results. He feels
his team excels in conducting clinical
trials simply and quickly.

https://jdc.jefferson.edu/translations/vol1/iss2/1

“I am proud that several of the ideas we
are currently working on were hatched
right here at Jefferson,” says Dr.
Flomenberg. Other ideas grew out of
developing novel ways to use existing
research. The division recently received
FDA approval and NCI funding for trials
that use the agent LLME (Leucyl-Leucine
Methyl Ester) in new ways beyond bone
marrow grafts. He has worked with
Robert Korngold, PhD, of the Kimmel
Cancel Center, and Joanne Filicko, MD,
to analyze the products and review the
data from these trials.
At its current size, the Medical Oncology
faculty is not able to address all of the
clinical, educational, research, and translational needs of the Department. Dr.
Flomenberg hopes to recruit six new
physicians to bolster clinical efforts in
the areas of lung cancer, gastrointestinal
malignancies, genitourinary oncology,
gynecologic oncology/breast cancer, and
developmental therapeutics.

2

He also sees possibilities in the area of
solid tumors. “Exciting things can also
be translated from the Kimmel Cancer
Center to clinical care,” says Dr.
Flomenberg. “The growth of Medical
Oncology will mean that even more of
the latest research in Jefferson’s basic
laboratories can find its way to clinical
trials that are performed here.”

Neal Flomenberg, MD (far right),
reviews results of recent clinical trials
with (left to right) Joanne Filicko, MD;
Robert Korngold, PhD; and Thea
Friedman, PhD.

2
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Education

Pomerantz Leads Jefferson’s
Efforts in Biodefense

Implementation of the
80-Hour Workweek

Since Roger J. Pomerantz, MD, was
recruited to head the Division of Infectious
Diseases fourteen years ago, the field has
changed dramatically. The tragic events
on September 11, 2001, brought his
research into the limelight. Building upon
the work of Lance Simpson, PhD, the
Division of Environmental Medicine was
merged into the Infectious Diseases
Division, forming a collaboration that Dr.
Pomerantz says “has made Jefferson the
only medical research center in Philadelphia
that covers all aspects of bioterrorism.”

As of July 1, 2003, Jefferson introduced
a new initiative to be in accordance with
the Accreditation Council for Graduate
Medical Education (ACGME), which limits
to 80 the number of hours residents in
the department can work per week.

An internationally recognized AIDS
researcher, Dr. Pomerantz is also Director
of the Center for Human Virology and
Biodefense. Started in 1993, the Center
brings together eighteen full-time faculty
and more than one hundred others to
explore how the virus works on a
molecular level, as well as vaccine
development, viral vectors, and gene
therapy. The Center’s Mike Root, MD,
PhD, has focused on other biodefense
genetics, including SARS research and the
Ebola virus.
Dr. Pomerantz is quite sober about the
fact that, “though humans have unleashed
agents on each other for thousands of
years, we do it better now.” Of the viruses
(smallpox, influenza), toxins (Botulinum),
bacteria (Anthrax), and fungi, he focuses
on not just what is dangerous but what is
easy to make and distribute. He describes
the necessary defense against bioterrorism
as threefold: prevention, response, and
research, and feels that a good vaccine
with few side effects is one of the best
modes of prevention.
Since September 11 Dr. Pomerantz has
testified twice in Congress to underscore
the need for a better smallpox vaccine,
since the current vaccine was developed in
the 1790s. “Trying to use an 18th-century
vaccine on a 21st-century population is a
problem,” says Dr. Pomerantz, “since today
there are so many people with suppressed
immune systems.” The smallpox vaccine
is still moderately effective, but has side
effects, as Dr. Pomerantz learned when
he got it himself two years ago.
He explains that the Department of
Medicine has developed a bioterrorism
response plan, to prevent patients going

Published by Jefferson Digital Commons, 2009

into surgery or the ER if beds are needed
by others. This plan has become a model
for the entire hospital. The good news is
that physicians training today will be
better equipped to react to these extreme
situations. This year the Infectious
Diseases and Internal Medicine boards
finally feature questions on bioterrorism,
and this
knowledge will
be required for
any internist.
The exceptional
research of Dr.
Pomerantz and
his team will
continue to be
one Jefferson’s
best defenses.

Roger Pomerantz, MD,
leads Jefferson’s research
in the area of biodefense.

Faculty News
New Faculty in the
Department
New to the Center of Translational
Medicine are Andrea Eckhart, PhD;
Donna Souders Woulfe, PhD; Erhe
Gao, MD, PhD; and Kurt Chuprin, PhD.
Christopher Hansen, MD, has joined
the Division of Cardiology as Director of
Nuclear Cardiology. Paul Mather, MD,
is the new Director of Heart Failure. Both
come to Jefferson from Temple University.
Internal Medicine has added several new
faculty members, including Jenny Wang,
MD; G. Robert Witmer, MD; David
Axelrod, MD; and Sammy Zakaria,
MD. Joining Clinical Pharmacology this
year is Inna Chervoneva, PhD. New
to Gastroenterology and Hepatology is
David Loren, MD. New to Infectious
Diseases is Renee Daniel, PhD. John
Friedewald, MD, has joined Nephrology,
and Chris Derk, MD, has joined
Rheumatology.
3

Gregory Kane, MD, Associate Professor
of Medicine and Director of the
Residency Program, emphasizes that the
Department has taken the new guidelines
quite seriously. “We have adapted our
schedule to afford time off for residents
so we can maintain the high quality of
patient care while residents purse their
educational goals,” he says.
The rationale for the guidelines is to
avoid accumulated sleep debt that can
result in deterioration of performance.
“Residents have always had one day off
a week during every inpatient block,”
says Dr. Kane. “The new plan increases
attention to hours during the week and
changes the on-call day so residents get
eight hours off for sleep on the night
they are on call. It also ensures that there
is a backup system for overwhelmed or
fatigued residents.”
Among the areas that are most changed
are the Intensive Care Units, where a
“float” resident has been added to cover
nights. Extra intern staff also have medical responsibilities in the ICU, where
there are now four instead of three
interns during most blocks. During weeknights on the floors, residents go home
at 10 p.m. and are on call, instead of
being up all night and admitting patients
on a 36-hour schedule. When residents
do stay overnight on weekends, the
maximum period for admitting new
patients is 24 hours, and residents always
go off duty within 30 hours.
Dr. Kane stresses the importance of
Jefferson acting as a national leader in
demonstrating compliance with the
regulations. “The Department feels this is
the right thing to do in order to train the
most outstanding internists,” he says. He
notes that the regulations bring the U.S.
more in line with countries in the European
Union and elsewhere internationally. The
Department’s Internal Medicine Residency
recently received notification of continued
full accreditation through the ACGME
with a five-year cycle length.
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Giving Jefferson Ideas Broader Access
Steven E. McKenzie, MD, PhD, has been
Director of the Cardeza Foundation for
Hematologic Research and the Division
of Hematology in the Department of
Medicine since 2000. In July 2003 he
was also appointed Vice President for
Science Policy and Technology Transfer.
In this new capacity Dr. McKenzie seeks
to help Jefferson faculty translate their
ideas in a way that can be of use to
other physicians.
The Bayh-Dole act of 1982 mandated
at a federal level that academic medical
centers receiving NIH funding also had
to convert their ideas into marketable
products. As a result several products
have emerged from the Department of
Medicine science labs, such as discovery
tools that enable more and better

research; preclinical models of discovery,
including mouse and other animal
models; and devices and agents that
are used for diagnosis, therapy, and
prevention of disease.
As a physician-scientist who sees patients
and also conducts research, Dr. McKenzie
interfaces between clinical and scientific
faculty and the university’s professional
Office of Technology Transfer (OTT).
Located in Jefferson Hall and directed
by Katherine Chou, this office brings
together OTT professionals with
Jefferson physicians and scientists.
“In much the same way that most
advanced medical science is done in
teams, this effort requires input from
multiple disciplines,” he says. The

(Left to right): Steven McKenzie, MD,
PhD, worked with Saul Surrey, PhD,
and Paolo Fortina, MD, PhD, to
translate their work with genetic
mutations into patentable methods.
Technology Transfer Advisory Committee –
composed of Dr. McKenzie, Ms. Chou,
University Counsel Alan Kelly, and Chief
Financial Officer Richard Schmid – unites
the various knowledge sources in order
to achieve these goals.
Continued on page 6

Project CARE
DeCaro Oversees Implementation of Project CARE in CCU

Matthew DeCaro, MD, reviews
Project CARE patient guidelines with
Heather Miller, RN, MSN, at left, and
Mary Vergara, RN.

https://jdc.jefferson.edu/translations/vol1/iss2/1

Dr. DeCaro also oversees the implementation of new in-patient guidelines from
Project CARE (Coordinated Approaches
Redesigned for Excellence). The initial
stages of Project CARE created detailed
but streamlined guidelines for acute
coronary syndrome and congestive heart
failure, which account for a significant
percent of CCU admissions. After being
formalized to meet ACC and AHA
standards, the guidelines were introduced
last fall in 22 beds on 5 West, which
Dr. DeCaro says “acts as a testing
ground for the implementation of Project
CARE on the unit overall.” The paper
order sets have been in place for several
months and will be also be available
electronically when the order entry
goes online.
Dr. DeCaro stresses that the efforts of
Howard Weitz, MD; Geno Merli, MD;
and Rebecca O’Shea, Vice President for
Clinical Program Development, have
been critical to the implementation of
Project CARE. He meets monthly with an
executive oversight group to review the
integration of CARE guidelines.

4

Recently Dr. DeCaro has begun to track
statistics in order to compare outcomes
from patients treated under the new
guidelines, “in terms of quality of care
and how they impact patients’ length
of stay,” he explains. The preliminary
review shows that patients are being
discharged earlier, which helps with
patient flow. There has also been an
increase in efficiency, “since the house
staff has a critical mass of patients on
the unit and spends most of their time
there,” he says. The executive committee
will soon begin work on the next two
diagnoses (atrial fibrillation and
community-acquired pneumonia).
Dr. DeCaro says he appreciates the
opportunity to focus on education and
to champion with the administration
issues raised by the nursing and house
staff. “Critical to our success have been
the efforts of Heather Miller, RN, nurse
manager, and Mary Vergara, RN, on our
implementation team,” says Dr. DeCaro.
“Their leadership has already made this
a very successful team effort.”

4
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In July 2003 Matthew DeCaro, MD,
Clinical Assistant Professor of Cardiology,
assumed the newly created position of
Coronary Care Unit Director. In this role
he is responsible for 24-hour patient
care, overseeing patient admissions and
flow, and managing the triage of
high-acuity patients so that only the
most critical are admitted to the CCU.
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Eugene Feiner Makes a
Habit of Making a
Difference

he himself once knew.” Gene feels that
generosity is part of his success: “There
is enough for everybody,” he says.

The opening on November 14, 2003, of
the Center for Translational Medicine
and the Eugene Feiner Laboratory for
Vascular Biology and Thrombosis was an
historic event for the Department. But it
was a bit more routine for Gene Feiner,
for whom philanthropy is part of everyday life.

Philanthropic efforts have been a commitment since Gene was a young businessman, but since selling his company
in 1997 he has made it a priority. A
member of the Thomas Jefferson
University President’s Club, he was also
the Variety Club’s Man of the Year in
2001.

Always a forward-thinker, Gene took
great pride early in his career in making
new possibilities a reality. He began to
work for the Acme Manufacturing
Company, then a modest local business,
and over the decades built it into one of
the largest manufacturers of its kind in
the United States.

A special interest in Israel has led Gene
to fund a number of initiatives there,
including a school library and recreation
center in Haifa, where in June 2001 he
received the key to the city. When asked
about the five Russian orphans he sponsors in Israel, he says, “to save one person is to save the world,” citing the
Hebrew expression “Tikkun olam”
(repair the world).

Close friend and colleague Martin
Coopersmith, who has known Gene
some forty years, says Gene’s “belief in
the premise of giving back and his interest in knowing and helping people
comes from the modest circumstances

Gene met Geno Merli, MD, and Howard
Weitz, MD, some ten years ago, and has
been a patient and friend of Jefferson
ever since. “Meeting doctors as person-

Recent Gifts
A plaque in honor of Margaret Kennedy
Detwiler was dedicated at a ceremony
on the 8th floor of the College Building
on October 24, 2003. In her honor the
Roberts and Detwiler families made a gift
to the Department of Medicine and the
Department of Family Medicine. There to
honor Mrs. Detwiler were (below, left to
right): cardiologist Reginald Ho, MD;
Gregory Kane, MD, representing
Pulmonary Medicine; her husband
Donald Detwiler; her daughter Aileen
Roberts and son-in-law Brian Roberts,
Chief Executive Officer of Comcast; and
Anthony DiMarino, Jr., MD, Director of
Gastroenterology and Hepatology.

Published by Jefferson Digital Commons, 2009

Eugene Feiner (right) and Geno Merli,
MD, celebrate the opening of the
Eugene Feiner Laboratory for Vascular
Biology and Thrombosis on the 4th
floor of the College Building.
able as Geno and Howard, you sense
their compassion as well as their expertise,” he says. “That is the best that
medicine today has to offer. It inspires
me to help make possible research that
will impact the livelihood of future
generations in such an important way.”
To learn more about giving opportunities
or to make a donation to the Department
of Medicine or one of our physicians,
please contact Susan Schiffrin at
215-955-7556 or via e-mail at
susan.schiffrin@jefferson.edu.

T

In Memoriam:
Daniel M. Tabas

The Datz and Murray families came
together on October 21, 2003, in
gratitude for the work of the Division of
Rheumatology in the area of scleroderma.
A gift was made in memory of John
Murray, who helped raise significant
funds for research that helped many
fight the disease. Mr. Murray was
tragically killed in the World Trade Center
on September 11, 2001. In attendance
were (above, left to right) his daughter
Alyson Murray, wife Rory Murray,
father Philip Murray, and sister
Cathy Datz, as well as Director of
Rheumatology Sergio Jimenez, MD.

5

We have been greatly saddened by the
loss of Daniel M. Tabas in 2003, who
was not only a patient, but also a good
friend of Jefferson and Drs. James Burke
and Roger Daniels for many years.
Among the many examples of Mr. Tabas’s
generosity was the new nephrology suite
he made possible at 833 Chestnut Street,
7th floor (below), which now serves our
patients with improved space and
equipment. We recognize the legacy
Dan left to the Tabas Family, his wife,
Evelyn, their children, Lee and Nancy
Tabas, Linda and Murray Stempel, Jo
Ann and Howard Wurzak, Carol Tabas,
Robert and Janine Tabas, and Susan
Tabas Tepper, and know that Dan’s spirit
of philanthropy will live on through them.

5
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Segal Honored at
125th Gala
On Thursday, November 20, Bernard
Segal, MD, Chief of the Division of
Cardiology and Director of the Jefferson
Heart Institute, was honored at the
Thomas Jefferson University Hospital
Anniversary Gala. This event was held in

Honoree Bernard Segal, MD (right),
receives congratulations from his
wife, Idajane Segal, and hospital
President and CEO Thomas J. Lewis.

the Grand Ballroom of the Philadelphia
Marriott Hotel, in celebration of the hospital’s 125 years of service to the greater
Philadelphia community.
Dr. Segal received the hospital’s first
Achievement Award in Medicine, for
attaining excellence in his profession and
for actively contributing to the growth
and development of his field. A video
tribute to Dr. Segal featured the praise,
esteem, and thanks of many of his
Jefferson colleagues. In his remarks, Dr.
Segal gave thanks to the many people
who worked with him in the field of
cardiology over the years.
Co-chairs for the 125th anniversary gala
were Lynne and Harold Honickman,
Geraldine and Richard Fox, Jane and
Leonard Korman, and Josephine C.
Mandeville. “Bernard Segal truly exemplifies service to Jefferson University
Hospital and the Delaware Valley,” said
Lynne Honickman. “It is through his
tireless efforts that Jefferson University
Hospital is one of the finest hospitals in
our region and across the country.”

Technology Transfer
Continued from page 4

One example of technology transfer
grew out of the work of Paolo Fortina,
MD, PhD, of the Center for Translational
Medicine, and the Cardeza Foundation’s
Saul Surrey, PhD. With funding from the
National Cancer Institute (NCI), they
developed new ways for detecting and
diagnosing genetic mutations in disease.
This led to funding and patent applications for these new methods. “We hope
now to license this technology in order
to get it into the hands of other investigators,” says Dr. McKenzie. Similar partnerships are currently in the works at
Jefferson in the areas of vascular biology
research, red blood cell and hemoglobin
disorders, and bone marrow disorders
and hematological malignancy.
Dr. McKenzie points out that the goals
of Technology Transfer in many ways
represent the best in medicine. “This
division is a microcosm of what we do
in the university as a whole – join with
members of other departments to
generate ideas in order to best help
patients.” For more information visit
www.jefferson.edu/ott/.
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